An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00097929
Phase
PHASE2
Status
Completed

Conditions

  • B-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.

Key Dates

Start date
May 1, 2005
Status verified
Apr 2017
Primary completion
Jul 31, 2006
Completion
Jul 31, 2006

Study Design

Enrollment
18 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective response rate based on FDG-PET and CT scan findings.

Related Studies